JP2018509388A5 - - Google Patents

Download PDF

Info

Publication number
JP2018509388A5
JP2018509388A5 JP2017539419A JP2017539419A JP2018509388A5 JP 2018509388 A5 JP2018509388 A5 JP 2018509388A5 JP 2017539419 A JP2017539419 A JP 2017539419A JP 2017539419 A JP2017539419 A JP 2017539419A JP 2018509388 A5 JP2018509388 A5 JP 2018509388A5
Authority
JP
Japan
Prior art keywords
composition
polypeptide
subject
hemolysis
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017539419A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018509388A (ja
JP6640229B2 (ja
Filing date
Publication date
Priority claimed from PCT/US2015/035473 external-priority patent/WO2015191951A2/en
Application filed filed Critical
Priority claimed from PCT/US2016/015412 external-priority patent/WO2016123371A1/en
Publication of JP2018509388A publication Critical patent/JP2018509388A/ja
Publication of JP2018509388A5 publication Critical patent/JP2018509388A5/ja
Priority to JP2019233666A priority Critical patent/JP6915034B2/ja
Application granted granted Critical
Publication of JP6640229B2 publication Critical patent/JP6640229B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017539419A 2015-01-28 2016-01-28 補体活性の変調剤 Active JP6640229B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019233666A JP6915034B2 (ja) 2015-01-28 2019-12-25 補体活性の変調剤

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562108772P 2015-01-28 2015-01-28
US62/108,772 2015-01-28
USPCT/US2015/035473 2015-06-12
PCT/US2015/035473 WO2015191951A2 (en) 2014-06-12 2015-06-12 Modulation of complement activity
US201562185298P 2015-06-26 2015-06-26
US62/185,298 2015-06-26
PCT/US2016/015412 WO2016123371A1 (en) 2015-01-28 2016-01-28 Modulators of complement activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019233666A Division JP6915034B2 (ja) 2015-01-28 2019-12-25 補体活性の変調剤

Publications (3)

Publication Number Publication Date
JP2018509388A JP2018509388A (ja) 2018-04-05
JP2018509388A5 true JP2018509388A5 (enExample) 2019-03-07
JP6640229B2 JP6640229B2 (ja) 2020-02-05

Family

ID=56544343

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017539419A Active JP6640229B2 (ja) 2015-01-28 2016-01-28 補体活性の変調剤
JP2019233666A Active JP6915034B2 (ja) 2015-01-28 2019-12-25 補体活性の変調剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019233666A Active JP6915034B2 (ja) 2015-01-28 2019-12-25 補体活性の変調剤

Country Status (14)

Country Link
US (6) US9937222B2 (enExample)
EP (2) EP3988110A1 (enExample)
JP (2) JP6640229B2 (enExample)
CY (1) CY1124761T1 (enExample)
ES (1) ES2900998T3 (enExample)
HR (1) HRP20211824T1 (enExample)
HU (1) HUE056613T2 (enExample)
LT (1) LT3250230T (enExample)
PL (1) PL3250230T3 (enExample)
PT (1) PT3250230T (enExample)
RS (1) RS62630B9 (enExample)
SI (1) SI3250230T1 (enExample)
SM (1) SMT202100688T1 (enExample)
WO (1) WO2016123371A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102346228B1 (ko) 2014-06-12 2022-01-04 라 파마슈티컬스 인코포레이티드 보체 활성의 조절
EP3988110A1 (en) 2015-01-28 2022-04-27 RA Pharmaceuticals, Inc. Modulators of complement activity
SG11201804721SA (en) * 2015-12-16 2018-07-30 Ra Pharmaceuticals Inc Modulators of complement activity
JP7301741B2 (ja) * 2016-12-07 2023-07-03 ラ ファーマシューティカルズ インコーポレイテッド 補体活性のモジュレータ
KR102656199B1 (ko) 2017-04-21 2024-04-09 볼루션 이뮤노 파마슈티컬스 에스에이 자가면역 수포 질환의 치료를 위한 코버신
WO2018193120A1 (en) * 2017-04-21 2018-10-25 Volution Immuno Pharmaceuticals Sa Coversin for the treatment of cicatrising eye inflammatory disorders
EP3870221A1 (en) 2018-10-22 2021-09-01 RA Pharmaceuticals, Inc. Neurological disease treatment with zilucoplan
WO2020247607A1 (en) 2019-06-04 2020-12-10 Ra Pharmaceuticals, Inc. Inflammatory disease treatment with complement inhibitors
JP6773930B1 (ja) 2019-08-09 2020-10-21 住友化学株式会社 液晶ポリエステル樹脂成形体、液晶ポリエステル樹脂ペレット、及び液晶ポリエステル樹脂ペレットの製造方法
CA3150594A1 (en) 2019-09-12 2021-03-18 Ra Pharmaceuticals, Inc. Neurological disease treatment with complement inhibitors
WO2022177635A2 (en) * 2021-02-22 2022-08-25 Ra Pharmaceuticals, Inc. Compositions and methods for microbial disease treatment

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6361943B1 (en) 1996-10-17 2002-03-26 Mitsubishi Chemical Corporation Molecule that homologizes genotype and phenotype and utilization thereof
US4271068A (en) 1968-05-10 1981-06-02 Ciba-Geigy Corporation Process for the manufacture of cystine-containing peptides
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4033940A (en) 1975-11-12 1977-07-05 Armour Pharmaceutical Company Cyclization of peptides
US4216141A (en) 1978-07-19 1980-08-05 The Salk Institute For Biological Studies Method for cyclization of peptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
NZ199722A (en) 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US6309669B1 (en) 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5371109A (en) 1986-07-01 1994-12-06 Drilletten Ab Controlled release composition for a biologically active material dissolved or dispersed in an L2-phase
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DK0494955T3 (da) 1989-10-05 1998-10-26 Optein Inc Cellefri syntese og isolering af hidtil ukendte gener og polypeptider
US5585353A (en) 1990-02-02 1996-12-17 The Rockefeller University Antibiotic peptides containing D-amino acids
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5843701A (en) 1990-08-02 1998-12-01 Nexstar Pharmaceticals, Inc. Systematic polypeptide evolution by reverse translation
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
EP0700522A1 (en) 1993-05-28 1996-03-13 Chiron Corporation Method for selection of biologically active peptide sequences
PT710243E (pt) 1993-06-29 2000-11-30 Ferring Bv Sintese melhorada de peptidos ciclicos.
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5834318A (en) 1995-05-10 1998-11-10 Bayer Corporation Screening of combinatorial peptide libraries for selection of peptide ligand useful in affinity purification of target proteins
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US6720472B2 (en) 1996-07-12 2004-04-13 University Of Medicine And Dentistry Of New Jersey HMGI proteins in cancer and obesity
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6348584B1 (en) 1996-10-17 2002-02-19 John Edward Hodgson Fibronectin binding protein compounds
US5922680A (en) 1996-10-23 1999-07-13 Ferring, B.V. Stabilized composition for oral administration of peptides
US6261804B1 (en) 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
WO1998031700A1 (en) 1997-01-21 1998-07-23 The General Hospital Corporation Selection of proteins using rna-protein fusions
US5990237A (en) 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
CA2293632C (en) 1997-06-12 2011-11-29 Research Corporation Technologies, Inc. Artificial antibody polypeptides
EP0896001A1 (en) 1997-08-08 1999-02-10 Daicel Chemical Industries, Ltd. Method for preparing oxytocin antagoniste derivatives, intermediates for the preparation of oxytocin antagonist derivatives and method for preparing the intermediates
US6429301B1 (en) 1998-04-17 2002-08-06 Whitehead Institute For Biomedical Research Use of a ribozyme to join nucleic acids and peptides
CN1313439C (zh) 1998-08-07 2007-05-02 艾米斯菲尔技术有限公司 用于送递活性剂的化合物和组合物
AU1705100A (en) 1998-10-09 2000-05-01 Musc Foundation For Research Development Blocking factor b to treat complement-mediated immune disease
US6962781B1 (en) 2000-05-19 2005-11-08 Proteonova, Inc. In vitro evolution of nucleic acids and encoded polypeptide
US7244701B2 (en) 2000-06-16 2007-07-17 Zealand Phama A/S Diuretic peptide conjugate
CA2524534C (en) 2003-05-15 2012-12-11 Sek Chung Fung Methods and compositions for the prevention and treatment of sepsis
US7348401B2 (en) 2003-09-10 2008-03-25 Innate Biotech, Inc. Peptides that inhibit complement activation
EP1706098A4 (en) 2003-11-26 2012-08-15 Supernus Pharmaceuticals Inc MICELLAR SYSTEMS SUITABLE FOR THE DELIVERY OF LIPOPHILIC OR HYDROPHOBIC COMPOUNDS
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
US20060027059A1 (en) 2004-08-09 2006-02-09 Chih-Ching Hsien Extendable handle device
US20090054623A1 (en) 2004-12-17 2009-02-26 Neose Technologies, Inc. Lipo-Conjugation of Peptides
JP5372380B2 (ja) 2005-01-24 2013-12-18 ペプスキャン システムズ ベー.フェー. 結合化合物、免疫原性化合物およびペプチド模倣体
CA2610502A1 (en) 2005-03-29 2006-10-05 Cardax Pharmaceuticals, Inc. Reduction in complement activation and inflammation during tissue injury by carotenoids, carotenoid analogs, or derivatives thereof
WO2006128006A1 (en) 2005-05-26 2006-11-30 The Regents Of The University Of Colorado Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
US8546326B2 (en) 2005-06-06 2013-10-01 Camurus Ab Glp-1 analogue formulations
ZA200803659B (en) 2005-11-04 2009-07-29 Genentech Inc Use of complement pathway inhibitors to treat ocular disease
KR20080110800A (ko) 2006-03-15 2008-12-19 알렉시온 파마슈티칼스, 인코포레이티드 보체의 저해물질로 발작성 야간혈색뇨증 환자의 치료
EP1876183A1 (en) 2006-07-04 2008-01-09 Technische Universität München Minimized small peptides with high affinity for factor VIII and factor VIII-like proteins
CA2666466C (en) 2006-10-10 2017-11-14 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Complement inhibition for improved nerve regeneration
US7736860B2 (en) 2006-11-09 2010-06-15 Univeristy Of Massachusetts Methods of identifying compounds for the treatment of sterile inflammation
JP2010520309A (ja) 2007-03-06 2010-06-10 ノボ・ノルデイスク・エー/エス 出血関連性炎症を治療するための補体系活性化の調節
KR20100015773A (ko) 2007-03-22 2010-02-12 노파르티스 아게 C5 항원 및 그의 용도
US20100015139A1 (en) 2008-07-10 2010-01-21 Rekha Bansal METHOD OF INHIBITING COMPLEMENT ACTIVATION WITH FACTOR Ba SPECIFIC ANTIBODIES AND USE THEREOF
CA2680833A1 (en) 2007-04-30 2008-11-13 Alcon Research, Ltd. Treatment of age-related macular degeneration using inhibitors of complement factor d
JP5683265B2 (ja) 2007-06-07 2015-03-11 ジェネンテック, インコーポレイテッド 補体が関係している障害の予防および処置のためのc3b抗体ならびに方法
WO2009014633A1 (en) 2007-07-20 2009-01-29 Trustees Of The University Of Pennsylvania Method of treating acute respiratory distress syndrome
WO2009046198A2 (en) 2007-10-02 2009-04-09 Potentia Pharmaceuticals, Inc. Sustained delivery of compstatin analogs from gels
WO2009067191A2 (en) 2007-11-16 2009-05-28 The General Hospital Corporation Methods and compositions for the treatment of hepatitis c virus (hcv) infection
US20110190221A1 (en) 2008-03-28 2011-08-04 Apellis Ag Modulation and repletion/enhancement of the complement system for treatment of trauma
WO2010014830A2 (en) 2008-07-30 2010-02-04 Cosmix Therapeutics Llc Peptide therapeutics that bind vegf and methods of use thereof
EP2331561A4 (en) 2008-09-03 2013-02-27 Xenome Ltd PEPTIDE CONJUGATE LIBRARIES AND METHODS OF MAKING SAME
EP2894166A1 (en) 2008-11-10 2015-07-15 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
WO2011047346A1 (en) 2009-10-16 2011-04-21 Omeros Corporation Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation
NZ600393A (en) 2009-11-05 2014-08-29 Alexion Cambridge Corp Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
WO2011080102A2 (en) 2009-12-16 2011-07-07 Novo Nordisk A/S Glp-1 analogues and derivatives
US9172511B2 (en) 2009-12-24 2015-10-27 Samsung Electronics Co., Ltd. Apparatus and method of communicating automatic repeat request (ARQ) feedback in a wireless communication network
WO2011106635A1 (en) 2010-02-25 2011-09-01 The Trustees Of The University Of Pennsylvania Treatment of sepsis using complement inhibitors
WO2011137363A1 (en) 2010-04-30 2011-11-03 Allergan, Inc. Novel treatment for age related macular degeneration and ocular ischemic disease associated with complement activation by targeting 5-lipoxygenase
TW201241008A (en) 2010-10-01 2012-10-16 Alexion Pharma Inc Polypeptides that bind to human complement component C5
BR112013025917A2 (pt) 2011-04-08 2016-12-20 Omeros Corp uso de um anticorpo masp-2 ou fragmento do mesmo que inibe ativação de complemento dependente de masp-2
WO2012162215A1 (en) 2011-05-20 2012-11-29 The Trustees Of The University Of Pennsylvania Promotion of fracture healing using complement inhibitors
WO2012174055A1 (en) 2011-06-13 2012-12-20 The Trustees Of The University Of Pennsylvania Wound healing using complement inhibitors
CN102321170B (zh) 2011-09-14 2013-11-13 深圳翰宇药业股份有限公司 利拉鲁肽变构体及其缀合物
US20140296147A1 (en) 2011-10-06 2014-10-02 The Medicines Company Methods of treating or preventing blood loss during surgery using the serine protease inhibitor mdco-2010
SMT201900189T1 (it) * 2012-02-20 2019-05-10 Swedish Orphan Biovitrum Ab Publ Polipeptidi che si legano al c5 del complemento umano
MX338806B (es) * 2012-02-21 2016-04-29 Production Sciences Inc Sistema y método para medir la velocidad de flujo del pozo.
US20130246083A1 (en) 2012-03-16 2013-09-19 Alexion Pharmaceuticals, Inc. Methods of distributing complement-inhibiting drugs to patients receiving a complement inhibitor
US9238676B2 (en) 2012-05-17 2016-01-19 Ra Pharmaceuticals, Inc. Peptide and peptidomimetic inhibitors
US9579360B2 (en) 2012-06-20 2017-02-28 The Trustees Of The University Of Pennsylvania Methods of treating or preventing periodontitis and diseases associated with periodontitis
WO2014004733A1 (en) 2012-06-26 2014-01-03 The Regents Of The University Of California Composition for lupus nephritis and methods of making and using the same
WO2014078622A1 (en) 2012-11-15 2014-05-22 The Brigham And Women's Hospital, Inc. Method and system for diagnosing and treating preeclampsia
US9700633B2 (en) 2013-01-28 2017-07-11 Jenkem Technology Co., Ltd., Tianjin Branch Conjugates of water soluble polymer-amino acid oligopeptide-drug, preparation method and use thereof
US20140234275A1 (en) 2013-02-15 2014-08-21 Jason Williams Method for treating als via the increased production of factor h
WO2015025312A1 (en) 2013-08-21 2015-02-26 Cannabics Pharmaceuticals Inc Compositions for combined immediate and sustained release of cannabinoids, methods of manufacture and use thereof
WO2015140304A1 (en) 2014-03-20 2015-09-24 Inflarx Gmbh Inhibitors of c5a for the treatment of viral pneumonia
KR102346228B1 (ko) 2014-06-12 2022-01-04 라 파마슈티컬스 인코포레이티드 보체 활성의 조절
US20160168237A1 (en) 2014-12-12 2016-06-16 Alexion Pharmaceuticals, Inc. Method for treating a complement mediated disorder caused by an infectious agent in a patient
EP3142656B1 (en) 2015-01-21 2018-10-17 Pacira Pharmaceuticals, Inc. Multivesicular liposome formulations of tranexamic acid
EP3988110A1 (en) * 2015-01-28 2022-04-27 RA Pharmaceuticals, Inc. Modulators of complement activity
WO2017035362A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Use of complement pathway inhibitor compounds to mitigate adoptive t-cell therapy associated adverse immune responses
SG11201804721SA (en) 2015-12-16 2018-07-30 Ra Pharmaceuticals Inc Modulators of complement activity
JP7301741B2 (ja) 2016-12-07 2023-07-03 ラ ファーマシューティカルズ インコーポレイテッド 補体活性のモジュレータ
US10376595B2 (en) 2017-04-03 2019-08-13 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of C5a activity
EP3682016A4 (en) 2017-09-11 2021-06-02 RA Pharmaceuticals, Inc. FORMULATIONS FOR THE ADMINISTRATION OF COMPOUNDS
WO2019112984A1 (en) 2017-12-04 2019-06-13 Ra Pharmaceuticals, Inc. Modulators of complement activity
TW202100179A (zh) 2019-03-08 2021-01-01 美商Ra製藥公司 補體活性之調節劑
KR20220004039A (ko) 2019-04-24 2022-01-11 라 파마슈티컬스 인코포레이티드 보체 활성을 조절하기 위한 조성물 및 방법

Similar Documents

Publication Publication Date Title
JP2018509388A5 (enExample)
MX2023012450A (es) Esketamina para el tratamiento de la depresion.
JP2017158561A5 (enExample)
JP2015517488A5 (enExample)
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
IL273194B2 (en) Methods, compounds and compositions for treatment of parainfluenza virus in immunocompromised patients
EP4233861A3 (en) Compositions for treatment of essential tremor
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
JP2015518818A5 (enExample)
NZ713202A (en) Diagnosis and treatments relating to th2 inhibition
MX2019013279A (es) Metodos de tratamiento del sindrome de doose utilizando fenfluramina.
EA201492010A1 (ru) Применение высокой дозы лахинимода для лечения рассеянного склероза
BR112015010396A2 (pt) terapia de combinação
SG10201901242PA (en) Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia
NZ608502A (en) Polypeptides that bind to human complement component c5
JP2011225596A5 (enExample)
WO2013188210A3 (en) Treatment of side effects associated with parkinson's disease treatments
EP4279128A3 (en) Novel antibody binding to tfpi and composition comprising the same
CA2986891C (en) Compositions for use in treating parkinson's disease and related disorders
EP4578461A3 (en) Methods of treating parkinsons disease by administration of apomorphine to an oral mucosa
JP2018529666A5 (enExample)
JP2017519762A5 (enExample)
JP2016512247A5 (enExample)
ZA202106768B (en) Triamterene or nolatrexed for use in the treatment of phenylketonuria
RU2015112121A (ru) Ми-рнк и их применение в способах и композициях для лечения и/или профилактики глазных состояний